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Abstract
Evaluation of myocardial perfusion and viability in patients with 
stable coronary artery disease have now become the basic 
source of information in qualification for revascularization or 
optimal medical therapy. This article describes all the available 
methods of non-invasive imaging of myocardial perfusion and 
viability.
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Introduction
The 2010 European Society of Cardiology guidelines concer­
ning the indications for revascularisation [1] define, based on the 
results of clinical studies and multi­centre meta­analyses, the role 
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of myocardial perfusion and viability assessments in the qualifica­
tion of patients with coronary artery disease for further therapeutic 
management. 
Based on these guidelines, myocardial perfusion assessment 
complete with the diagnosis of the extent and location of perfusion 
disorders provides the basis for the selection of patients with stable 
coronary artery disease or intermediate probability of coronary 
artery disease and normal resting contractility of the left ventricle 
for further invasive diagnostic (coronary angiography) and treat­
ment (revascularisation) procedures [2]. 
And also, based on the same guidelines, myocardial viability 
assessment focused on the region supplied by the narrowed/oc­
cluded coronary artery forms the basis for the selection of pa­
tients with impaired contractility of the left ventricle for revascu­
larisation [3, 4].
It is important that both these cases are relevant to stable 
patients or patients with intermediate probability of coronary artery 
disease for whom the postponement of therapeutic procedure by 
attempting preliminary non­invasive diagnostic methods should 
not cause any irreversible myocardial changes (necrosis) or any 
other major adverse cardiac events (MACE) [2]. Patients diagnosed 
using non­invasive methods for perfusion and viability assessment 
are those for whom it is possible — under no time pressure — ‘cito’ 
— to consider the benefits and drawbacks of the selected dia­
gnostic and treatment procedures, and to prepare an appropriate 
management plan based on the clinical data and test results of 
a given patient. As has been stressed by the authors of the current 
guidelines concerning the indications for revascularisation, many 
patients should rather be considered eligible for planned coronary 
artery bypass grafting (CABG) than for emergency percutane­
ous transluminal coronary angioplasty (PTCA). 
Individualisation of therapeutic procedures has now become 
the order of the day as a result of many years of experience and 
efficacy assessment of revascularisation versus optimal pharma­
cological therapy. 
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Myocardial perfusion 
Stable coronary artery disease causes insufficient blood supply 
to the myocardium during physical exertion (or under stress) and 
thus restricts patient’s physical performance — the impairment 
of the coronary flow reserve is indicated under stress by such 
symptoms as coronary pain or its equivalent. The lack of these 
symptoms referred to as “silent ischemia” poses a danger for 
patients — it does not restrict their activity, does not trigger any 
danger signal and therefore can cause irreversible myocardial 
changes (necrosis). Patients with stable coronary artery disease 
can have normal resting myocardial contractility, which does not 
exclude stress­induced impairment of myocardial contractile 
function during physical exertion or immediately thereafter (hi­
bernating and/or stunned myocardium). In the COURAGE study, 
in a subset of 300 patients with significant coronary stenosis who 
underwent revascularisation, the reduced risk of a major adverse 
cardiac event (MACE) was only reported for those patients who 
were observed to have an area of more than 10% of left ventricle 
affected with stress­induced blood supply disorders before the 
procedure — only those patients benefited from invasive treatment 
compared to optimal medical therapy [5]. 
Therefore a well­planned revascularisation procedure should 
aim at eliminating ischemia, and not only the coronary artery 
stenosis [6].
The best­known and most widely used methods for determi­
ning the location and extent of ischemia include perfusion scintig­
raphy (SPECT, single photon emission computed tomography) and 
echocardiography with pharmacological stress. Echocardiography 
with dobutamine stress allows doctors to assess the effects of 
ischemia, i.e. myocardial dysfunction. Such methods as single 
photon emission computed tomography (SPECT), positron emis­
sion tomography (PET) and cardiac magnetic resonance (CMR) 
enable direct assessment of myocardial perfusion. PET and CMR 
are less available than SPECT, but the prospect of their develop­
ment and popularisation gives an opportunity of full quantitative 
assessment of myocardial blood flow (in mL/g/min) and coronary 
flow reserve. 
Myocardial viability 
The diagnosis of potentially irreversible myocardial dysfunction 
is important on account of the higher risk of death in patients with 
coronary artery disease and reduced myocardial contractility [7]. 
Only 57% of the patients suffering from coronary artery disease with 
left ventricular ejection fraction below 35% can survive 4 years com­
pared to the 92% survival rate among patients with ejection frac­
tion over 50% [3, 8]. Post­revascularisation myocardial damage 
is potentially reversible in about 25–40% of the patients with coro­
nary artery disease and LV dysfunction [9]. The meta­analysis of 
3088 patients with coronary artery disease demonstrated that the 
death rate was 4 times lower among post­surgical patients with 
dysfunctional, but viable myocardium compared to patients on 
pharmacological treatment [3]. No significant difference was de­
termined between the efficacy of pharmacological and surgical 
treatments among patients with no features of viable myocardium 
[3]. At the same time, one should be aware that the risk of death 
in the perioperative period and within a year from the coronary 
artery bypass graft (CABG) surgery in patients with permanent 
myocardial damage is twice as high compared to post­surgical 
patients with dysfunctional myocardium and retained myocardial 
viability (10% and 7.7% vs 4% and 3.2% respectively). About 35% 
of CABG or PTCA patients do not benefit from the treatment due to 
the fact that revascularisation comprises the region of transmural 
myocardial necrosis [3]. 
Therefore the differentiation between reversible and irreversible 
myocardial damage enables prompt and appropriate qualification 
of patients for revascularisation, i.e.:
 — selecting patients with potentially reversible damage who could 
benefit from surgical CABG or PTCA procedure;
 — selecting patients with irreversible damage who should avoid 
non­beneficial surgical procedures or operations which might 
only increase the risk of complications and death.
However, the results from the earlier reports and the recom­
mendations of the European Society of Cardiology (ESC) and 
the European Association for Cardio­Thoracic Surgery (EACTS) 
from 2010 are at variance with the results of the multicentre STICH 
study conducted in the years 2002­2007 among 2136 patients with 
ischemic myocardial dysfunction [10]. In the study, about half of the 
patients underwent SPECT or ECHO with dobutamine stress and 
they were not observed to derive greater benefits from surgical 
treatment compared to optimal medical therapy as a result of 
the retained myocardial viability. Ever since the publication of the 
STICH results in 2010, it has been discussed in the cardiological 
environment whether and how the limitations of the methodology 
selected for the study (PET or CMR instead of SPECT) could have 
affected the study results [11]. 
The diagnostic methods used for viability assessment are 
the same as those underlying perfusion assessment: echocar­
diography with dobutamine stress, perfusion scintigraphy, PET, 
MRI. Perfusion and viability assessments involve different study 
protocols and PET markers. 
Non-invasive imaging methods for 
myocardial perfusion and viability 
assessment 
1. SPECT-based myocardial perfusion and viability 
assessment
SPECT-BASED PERFUSION ASSESSMENT
Myocardial perfusion and viability assessment is based on 
myocardial perfusion scintigraphy, currently applied as a com­
puter­tomography method ­ single photon emission tomography 
(SPECT). Technetium­99m methoxyisobutylisonitrile (Tc­99m­MI­
BI), an isonitrile derivative most often used as a SPECT imaging 
agent, enables identifying the level of perfusion and also marking 
non­damaged myocyte cell membrane [12–15]. 
SPECT­based perfusion assessment comprises two phases: 
exercise (or pharmacological stress) phase and resting phase. 
The comparison of the distribution of the (perfusion) marker 
accumulation in the myocardium in each phase enables the 
assessment of transient ischemia (i.e. reduced coronary flow 
reserve) (Figure 1) and permanent ischemia (i.e. myocardial 
necrosis — for artefact differentiation) (Figure 2). In the scinti­
graphic perfusion assessment it is assumed that at least one of 
the three regions of the coronary blood flow is properly supplied 
48
Nuclear Medicine Review 2012, Vol. 15, No. 1
www.nmr.viamedica.pl
Review
with blood at rest and after stress — this reference region is nec­
essary to assess improper perfusion in other regions. Hence the 
method is referred to as semi­quantitative and may be unreliable 
in patients with multivessel coronary disease. The sensitivity and 
specificity of the SPECT procedure in the assessment of myocar­
dial ischemia is 85–90% and 70–75% respectively compared to 
coronary angiography results [2]. A region of improper perfusion 
larger than 10% of the left ventricle area [at least 2 segments in 
the 17­segment model (AHA)] is considered moderate to severe 
ischemia. Improper perfusion is most often defined as SD below 
2.5 compared to the proper perfusion distribution data for healthy 
volunteers in the normative computer data base (commercially 
available software for semi­quantitative assessment: QGS/QPS 
— Cedars­Sinai, 4D­MSPECT, University of Michigan, Emory 
Toolbox — Emory University). 
SPECT-BASED VIABILITY ASSESSMENT
Scintigraphic assessment of myocardial viability requires only 
resting SPECT image, and preferably resting ECG­gated SPECT 
(GSPECT) image. 
It is the cheapest and most widely available viability imaging 
method among 99m­Tc­MIBI­based functional SPECT proce­
dures — only a viable myocardium shows an appropriate level 
of perfusion at rest and systolic increase in the myocardial thick­
ness during GSPECT registration [16,17]. During GSPECT acquisi­
tion a viable myocardium shows at least 50% of the maximal marker 
accumulation compared to the reference best blood­supplied 
myocardial region (assuming that it is non­damaged myocardium) 
and systolic increase in the myocardial thickness of at least 10% 
in ECG­gated SPECT registration. These SPECT parameters show 
that the myocardial functions are likely to improve in more than 70% 
of post­revascularisation patients [17]. In other studies, the level 
of marker accumulation during SPECT registration below 30% of 
the maximal reference value shows that there is an 80% probability 
of myocardial non­viability, i.e. transmural or nearly transmural 
necrosis [14]. However, as shown in multicentre meta­analyses, 
SPECT­based viability values are overestimated and their specific­
ity is only 49% with sensitivity at 88% [18]. 
2. PET-based myocardial perfusion and viability 
assessment
PET-BASED PERFUSION ASSESSMENT
PET is considered a “gold standard” in myocardial perfusion 
assessment — the sensitivity and specificity of this method in the 
assessment of perfusion disorders in patients with coronary artery 
disease have been determined in 8 independent studies at 93–97% 
respectively — on average 93% and 88–100% — on average 92% 
[19], and furthermore it enables quantitative assessment of perfu­
sion in mL/g of myocardial tissue/min using N­13NH3 (nitrogen­13 
ammonia), O­15H2O (oxygen­15 water) or Rb­82Cl (rubidium­82 
chloride). However, these markers have a short half­life and except 
for Rb­82 need to be cyclotron­produced isotopes, and thus their 
cost is high. Nevertheless, only a fully quantitative assessment of 
coronary flow reserve and of coronary perfusion in mL/g/min during 
exercise and at rest can provide information whether and to what 
extent a patient with multivessel coronary disease suffers from 
impaired CFR of the myocardium supplied with blood through 
a narrowed coronary artery. 
Greater coronary flow under stress is referred to as the coro­
nary flow reserve (CFR) and measured as the ratio of the maximal 
blood flow to the blood flow at rest: coronary flow under stress/ 
/coronary flow at rest = CFR.
Under normal conditions, CFR exceeds 2 which means that 
the increased blood flow in a coronary vessel under stress is at 
least twice as high as at rest. 
If a sclerotic change in a coronary artery causes significant 
hemodynamic stenosis, then CFR decreases below 2 and reduced 
perfusion is observed in the myocardial region supplied by such 
coronary artery. Reduced CFR plays an important role in the 
development of indications for revascularisation [1,20], unless it 
exceeds 10% of the myocardial area in accordance with the ESC 
guidelines.
PET-BASED VIABILITY ASSESSMENT 
Fluorodeoxyglucose PET (FDG­PET) has recently been 
considered a “gold standard” in myocardial viability assessment 
[21], although currently this role has been taken over by MRI. In 
Figure 1. Myocardial perfusion SPECT study: stress (higher row) and 
rest (lower row) in short axis and also two-chamber and four- chamber 
long axis view. Reversible perfusion defects in anterior, apical, lateral 
and inferior myocardial walls are detected — decreased coronary flow 
reserve in more than 20% of left ventricle myocardium 
Figure 2. Myocardial perfusion SPECT study: stress (higher row) 
and rest (lower row) in short axis views. Persistent perfusion defect of 
infero-lateral wall at stress and rest intensifying at stress depicts sube-
picardial necrosis with still viable myocardium “at risk” in subepicardial 
part of these part of the wall
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a viable myocardium with reduced blood supply, glucose is used 
as a source of energy in anaerobic metabolism. An increased 
accumulation of F­18­labelled glucose in the dysfunctional region 
is indicative of retained myocardial viability and contributes to the 
greater probability of improved left­ventricular efficiency after revas­
cularisation [22, 23]. There are two criteria relevant to PET­based 
myocardial viability assessment: 1) properly supplied with blood 
and viable, but dysfunctional myocardium, i.e. proper perfusion 
with normal or increased FDG accumulation indicates stunned 
myocardium, 2) improperly supplied with blood and viable, but 
dysfunctional myocardium, i.e. reduced perfusion with normal 
or increased FDG accumulation indicates a strong probability of 
hibernated myocardium [24].
However, PET is a costly procedure and has lower spatial 
resolution than MRI with strong enhancement after gadolinium 
administration. The comparison of PET and MRI results showed 
95% compatibility [25].
3. CMR-based myocardial perfusion and viability 
assessment 
CMR-BASED PERFUSION ASSESSMENT 
The first pass of paramagnetic contrast agent through myo­
cardium, i.e. so­called ‘first­pass CMR’ is performed twice: under 
pharmacological stress (dipyridamole, adenosine) and at rest [26]. 
The aim of the procedure is to assess the enhancement of signal 
intensity during the first pass of contrast agent through myocar­
dium. The paramagnetic contrast agent reduces the relaxation 
time T1, i.e. the greater amount of the contrast agent flows into 
the coronary microcirculation with arterial blood, the higher is the 
signal intensity in a given LV myocardial segment. The CMR se­
quence used for registering perfusion ‘first­pass’ is Gradient Echo 
(GRE) — this very fast registration mode enables acquiring three 
short­axis images (basal, medial and apical) during one cardiac 
cycle. The images are recorded during subsequent phases of 
the cardiac cycle which enables dynamic registration of how the 
paramagnetic contrast agent flows through the cardiac cavities, 
and then to the coronary arteries and microcirculation with greater 
signal intensity in properly perfused regions of the myocardium. 
Signal intensity for the normal myocardium grows rapidly against 
time as opposed to the myocardium supplied by a narrowed 
coronary artery with delayed increase in signal intensity.
CMR procedure continues to improve; GRE sequence is modi­
fied in accordance with the technological development of MRI 
scanners, new paramagnetic contrast agents and new examina­
tion techniques are applied [27]. Currently, visual interpretation of 
perfusion images, including an assessment of the so­called signal 
intensity index during the first­pass CMR, plays a predominant role 
in everyday clinical practice. In the visual assessment it is assumed 
that at least one of the three regions of coronary blood supply 
shows normal perfusion at rest and normal coronary flow reserve 
under stress. This region is considered a reference region and the 
increase in its signal intensity is compared to the increase in signal 
intensity for the other myocardial segments. The result of the visual 
CMR­based perfusion assessment can be falsely negative in 3­vessel 
coronary artery disease, similarly as in the isotopic assessment of 
myocardial perfusion. Although there is a wide variety of computer 
programmes for semi­quantitative CMR­based perfusion assess­
ment, no consensus have been reached as to which one could 
replace visual assessment. The semi­quantitative CMR­based 
perfusion assessment still requires a reference region of properly 
perfused myocardium (similarly as in SPECT), but the measure­
ment of the intensity of perfusion disorders is numerical, and not 
subjective. Based on many years of experience, a range of different 
semi­quantitative parameters have been developed for the dynamic 
assessment of perfusion based on CT, SPECT and MRI examina­
tions of organs of less mobility than heart (brain, kidneys, liver): 
upslope of the time­signal intensity curve during the inflow of the 
contrast agent, area under the time­signal intensity curve, maximal 
signal intensity within a given time interval, time needed to achieve 
the maximal signal intensity within a given myocardial region.
Although there is a theoretical basis for a fully quantitative 
CMR­based perfusion assessment, new papers are continued to 
be published and discussions are ongoing on the optimal acqui­
sition protocol, dosage and rate of contrast agent administration 
as well as a post­processing programme which could enable 
precise and repeatable CFR assessment [28]. If a method for 
CMR­based perfusion procedure with quantitative perfusion as­
sessment is developed, then such procedure will have a signifi­
cant advantage over the quantitative PET­based assessment in 
multivessel coronary disease on account of the greater availability, 
lower price and lack of ionising radiation.
CMR-BASED VIABILITY ASSESSMENT 
Over the past few years a number of publications [29–31] 
included reports on CMR­based myocardial necrosis imaging 
after the administration of paramagnetic contrast agent and with 
the signal ratio for viable and non­viable myocardium of up to 
500%. This method known as ‘delayed enhancement’ (DE) or ‘late 
gadolinium enhancement’ (LGE) has been successfully used for 
determining the presence, location and extent of both acute and 
chronic myocardial necrosis. The location, shape and transmural 
extent of delayed enhancement in the myocardium during DE MR 
examination is morphologically identical to the extent of necro­
sis determined in tetrazolium­based histopathological examination 
[32]. Increased Gd­DTPA accumulation overlaps with the histologi­
cal cell changes in the necrotic region, typical of an infarct, and 
is about 130% higher than in a viable myocardium [33]. DE MR 
examination gives a possibility of determining the presence and 
extent of necrosis with spatial resolution greater than PET (gold 
standard thus far) or SPECT, and can be used to forecast improve­
ment of myocardial functions after revascularisation (Figure 3). 
Based on the results thus far, it was determined that the lack 
of delayed enhancement or the transmural extent of necrosis of 
up to 50% of the myocardial thickness increases the probability 
of post­revascularisation improvement of left­ventricular efficiency 
(Figure 4) [34]. 
Summary
Despite the existing discrepancies in the results of the useful­
ness studies concerning myocardial perfusion and viability as­
sessments when qualifying patients with coronary artery disease 
for revascularisation, it is the prevailing view among cardiolo­
gists that any such information is relevant and new, less invasive 
imaging methods increase the comfort of making therapeutic 
decisions which are correct and beneficial for patients. 
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Currently, the assessment of usefulness of non­invasive met­
hods for perfusion and viability analyses based on the author’s own 
experiences and available publications is given in the attached 
tables (Table 1, 2). The currently best results have been achieved 
for SPECT, including the cost of examination, its availability and 
objectivity. Similar requirements concerning myocardial viability 
assessment are satisfied by CMR. The classification presented 
in the tables can change rapidly as it depends both on the tech­
nological progress, which is very dynamic in CMR, as well as the 
availability and costs of PET. 
When analysing perfusion in patients with multivessel coro­
nary disease, one should take into account the limitations of the 
SPECT and CMR methods ­ under such circumstances PET 
continues to be the ‘gold standard’ with quantitative assessment 
of perfusion and coronary flow reserve, where such assessment 
requires non­available or hardly available markers (N­13NH3 — ni­
trogen­13 ammonia), O­15H2O ­ oxygen­15 water or Rb­82­rubid­
ium­82 chloride).
Figure 3. Comparison of delayed gadolinium enhancement magnetic 
resonance images (DE MR) and SPECT evaluation of transmural myo-
cardial necrosis of antero-septal wall (without viability): delayed gado-
linium enhancement MR (high row), SPECT with lack of tracer in area 
of MR contrast accumulation (middle row), image fusion of DE MR and 
SPECT images
Figure 4. Nearly transmural necrosis of anteroseptal and apical walls 
on DE MR image in 3-chamber view — without signs of viability in 
these area
Table 1. Myocardial perfusion assessment using various imaging diagnostic methods
Imaging method Availability Cost  
of examination








SPECT +++ ++ +++ +++ +/++
CMR ++(?) +++ ++/+++ +++(?) +(?)
PET – (?) ++++ ++++ ++++ ++++
ECHO with dobutamine +++ + +/++ +/++ +/++
Myocardial perfusion assessment based on non­invasive imaging methods — additionally included echocardiography with dobutamine aimed at analysing functional disorders, 
i.e. indirectly the effects of perfusion disorders; – — non­available method/no diagnostic value/non­objective assessment; + — low availability/low diagnostic value/low cost/ 
/reduced objectivity; ++ — moderate availability/moderate diagnostic value/moderate cost/good objectivity; +++ — good availability/reliable and objective diagnostic value/ 
/moderate cost; ++++ — widely available method/high objectivity/high cost;? — developing/growing in popularity
Table 2. Myocardial perfusion assessment using various imaging diagnostic methods
Imaging method Availability Cost  
of examination




SPECT +++ ++ ++/+++ +++
CMR ++(?) +++ ++++ ++++
PET +(?) ++++ ++++ ++++
ECHO with dobutamine +++ + +/++ +/++
Myocardial perfusion assessment based non­invasive imaging methods — additionally included echocardiography with dobutamine aimed at analysing the potential post­
revascularisation functional improvement;– — non­available method/no diagnostic value/non­objective assessment; + — low availability/low diagnostic value/low cost/reduced 
objectivity; ++ — moderate availability/moderate diagnostic value/moderate cost/moderate objectivity; +++ — good availability/reliable and objective diagnostic value/low cost; 
++++ — widely available method/high objectivity/high cost;? — developing/growing in popularity
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